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HIV is fuelling and disguising the full 
extent of South Africa’s TB pandemic 
that includes 6 000 multidrug-resistant 
patients (10% of whom are extremely 
drug resistant), creating a ‘critical need’ 
for a decentralised community-based 
approach while inexpensive point-of-
care diagnostics are developed.
This was the consensus among 
Médecins sans Frontières (MSF) doctors 
during a technical briefing of journalists 
in advance of the annual International 
Union of Tuberculosis and Lung Disease 
Conference held in Cape Town last 
month – the first time this country has 
ever hosted the event.
The MSF doctors, some of whom 
were part of the groundbreaking ART 
rollout in Khayelitsha, said South 
Africa was an obvious choice for the 
conference because of the intertwined 
HIV/TB epidemics and the growing 
emergence of XDR TB.
The conference presented a ‘golden 
opportunity’ to raise awareness of the 
difficulties imposed by the intertwined 
epidemics, the bottlenecks faced by a 
public health response due to the poor 
availability of drug and diagnostic 
tools and to explore urgently needed 
innovative approaches.
Professor Willem Sturm, Dean of the 
Nelson Mandela School of Medicine 
(University of KwaZulu-Natal) and 
head of the university’s microbiology 
laboratory, told Izindaba that by 
June this year XDR had spread to 68 
hospitals (two-thirds of the province’s 
health care facilities). By June this year 
they had identified 3 000 MDR patients 
and 308 XDR patients (most of the latter 
will be dead by the time you read this). 
The remainder of known drug-resistant 
patients are spread across every single 
other province in widely varying 
concentrations.
XDR was first detected by an alert 
Dr Tony Moll, Chief Medical Officer 
at Tugela Ferry’s Church of Scotland 
Hospital (COSH), who sent in sputum 
samples from perplexingly non-
responsive ART patients in 1995.
Sturm described XDR as ‘almost 
impossible to treat unless you have 
susceptibility testing’, adding that the 
only reason his province was better 
informed than many others was that 
when he first became KZN’s Head 
of Microbiology in 1993, he ordered 
susceptibility tests for all TB-positive 
cultures.
Learning from Tugela Ferry 
Two years of research at Tugela 
Ferry on the effect of administrative, 
environmental and personal infection 
control measures on the epidemic 
trajectory of XDR TB, using a 
mathematical model, predicts 1 300 
new cases in the immediate area by the 
end of 2012 – if no new interventions 
are introduced. The index cases in 2005 
numbered 53.
A heavyweight scientific team from 
Yale and KwaZulu-Natal universities 
predict that more than half of the 1 300 
cases will be nosocomially transmitted, 
adding that a combination of mask use, 
reduced hospitalisation time and a shift 
to outpatient therapy could prevent 
nearly a third of infections.
Supplementing this approach with 
improved ventilation, rapid drug 
resistance testing, HIV treatment and 
TB isolation facilities could avert 48% of 
XDR TB cases by the end of 2012, they 
conclude in a recent paper published in 
The Lancet (2007; 370: 1500-1507).
They warn that involuntary detention 
could result in an unexpected rise in 
incidence due to restricted isolation 
capacity at COSH (5-bed isolation units 
are recommended for the infective 
phase only). Similar to other rural 
district hospitals across the country, 
COSH has 30 - 40-bed open TB wards.
The crucially important findings are 
being studied and debated by clinicians 
across the country.
Sturm said drug resistance was 
difficult to identify in time to prevent 
further spread. Only concurrent 
isolation and treatment could mitigate 
a problem that he described as 
‘overwhelming’.
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A Tugela Ferry XDR TB patient in extremis,  
with his family in support.
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Dr Gilles van Cutsem, MSF co-
ordinator in Khayelitsha near Cape 
Town, said the lay media coverage of  
the TB pandemic had focused on the 
dramatic but relatively small number of 
MDR defaulters, virtually ignoring the 
largest pool of undiagnosed MDR cases 
walking around, not to mention those 
diagnosed and awaiting treatment, and 
those on treatment but still infectious.
‘You have virtually one bullet to kill 
MDR and if you fail, you have virtually 
no second chance. Once you have MDR 
you have to shoot with virtually every 
drug you can,’ he emphasised.
Sturm warnings went unheeded
Sturm has criticised the health 
department for not paying attention 
to his red flag waving about its 
treatment response in 1995. He 
provided evidence to back his 
contention by tracking the evolution 
of drug resistance in KwaZulu-Natal, 
the worst affected province, between 
1994 and 2002. By analysing samples 
of a highly transmissible strain called 
F15/LAM4/KZN he discovered that 
some patients were already resistant 
to treatment in 1995 – when the World 
Health Organization (WHO) advised 
South Africa to implement a four-drug 
combination for treating first-time 
TB patients (isoniazid, rifampicin, 
pyrazinamide and ethambutol). 
This meant that some patients 
were inadvertently getting a drug 
cocktail with only one or two effective 
ingredients, and so rapidly developed 
resistance to these drugs too. ‘I said to 
the health department then that it was 
a recipe for disaster but no one listened 
and MDR strains spread,’ he said.
Sturm claims that 6 years later, the 
same mistake was made when South 
Africa introduced WHO-approved 
guidelines stipulating which medicines 
to use for treating MDR TB – and 
the absence of susceptibility testing 
for second-line drugs this time led to 
the emergence of XDR TB. Patients 
got either ethambutol or cycloserine, 
in combination with pyrazinamide, 
ethionamide, kanamycin and 
ciprofloxacin or ofloxacin. Unknown 
to the health department, there was 
already resistance to both ethionamide 
and ethambutol, dating back to 1997. 
Sturm and his scientific team traced 
kanamycin resistance back to 1999 
and fluoroquinolone back to 2000. The 
researchers also found resistance to 
streptomycin as far back as 1994.
National health department 
TB Chief Dr Lindiwe Mvusi said 
routine susceptibility testing would 
be ‘impractical’ but confirmed that 
her department’s most recent drug 
resistance survey was done in 2001. She 
said an urgent new study was due to 
begin at the end of this year.
While Sturm sympathised with the 
difficulties of routine susceptibility 
testing, he said this did not mean that 
one could ignore continued surveillance 
‘in order to keep the finger on the 
pulse’.
The WHO estimates that 9 million 
people develop active TB globally every 
year, with 1.7 million deaths annually, 
while 80% of TB patients in sub-Saharan 
Africa are living with HIV.
AIDS hides TB infections
The  increasing prevalence of drug-
resistant TB in South Africa (as 
surveillance steps up) is complicated by 
HIV hugely increasing both the risk of 
developing active and extrapulmonary 
forms of TB, and rendering TB more 
difficult to diagnose due to a higher 
incidence of sputum-negative infection.
Less than half of HIV-positive people 
tested show up as TB smear-positive 
because of their immune-compromised 
systems.
The limited diagnostic tools and lack 
of laboratory capacity in South Africa 
(and many other African settings) 
aggravates the lack of timely detection 
of TB and MDR TB. Literally thousands 
of cases go undiagnosed and therefore 
untreated, fuelling the disease burden. 
When detected, centralised responses 
are often too overwhelmed to absorb 
the need, something that managers in 
the worst affected provinces in South 
Africa (KwaZulu-Natal and the Western 
Cape) have freely admitted. Funds are 
being poured into MDR-appropriate 
infrastructure but little exists on the 
ground in terms of decentralised 
community-based TB care.
MSF TB specialist Dr Cheryl 
A combination of mask use, 
reduced hospitalisation 
time and a shift to 
outpatient therapy could 
prevent nearly a third of 
infections.
Supplementing this 
approach with improved 
ventilation, rapid drug 
resistance testing, HIV 
treatment and TB isolation 
facilities could avert 48% of 
XDR TB cases by the end of 
2012.
Dr Tony Moll, principal medical officer at the 
Church of Scotland district hospital at Tugela 
Ferry helps a patient with her ARV drug 
compliance.
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McDermid said TB treatment was 
complicated by drug interactions and 
the side-effects of existing regimens. 
Inexpensive, sensitive, specific and 
rapid point-of-care diagnostic tests were 
‘still a long way away’.
‘We’ve been using the same drugs 
for 40 years,’ she emphasised, adding 
that this was in spite of TB having 
become the leading cause of death in 
low- and middle-income countries, 
with South Africa carrying the world’s 
highest incidence. She said the weak 
sterilising properties of ordinary TB 
drugs remained one of the biggest 
drawbacks that scientists faced. Current 
chemotherapy did not achieve a 
bacteriological cure.
McDermid said what was most 
needed was the shortening of first-
time treatment and for it to be effective 
against MDR – and that the regimen 
does not interact with ARV drugs. The 
tragedy was that TB and MDR TB were 
‘preventable and curable, yet it still kills 
one person every 15 seconds’.
Dr Mvusi released figures showing a 
0.5% increase in registered TB patient 
deaths from 2005 to last year (25 871 up 
to 29 787 mortalities) and portraying 
stark contrasts in the ability of different 
provinces to track patients.
KwaZulu-Natal fared worst with 
16.6% of registered patients known to 
have defaulted (probably higher as 9.1% 
were lost to follow-up) while 11.1% of 
Mpumalanga’s patients defaulted (10% 
here fell off the radar). The number 
of registered TB patients for the two 
provinces stand at 103 642 and 14 496 
respectively.
The country’s last recorded overall 
cure rate (1995) stands at 57.7%, well 
short of the WHO’s target of 85%. This 
represents a 7.1% rise on 2004 cure 
rates. New TB cases rose by 8% between 
2004 and 2005 (312 436 up to 337 309 
new cases).
The country is bracing itself for the 
latest morbidity and mortality figures.
Chris Bateman
‘I said to the health 
department then that it was 
a recipe for disaster but 
no one listened and MDR 
strains spread,’ he said.
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